Vincerx Pharma Announces FDA Clearance of IND for VIP943
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and...
COVID-19
StateHouse and Pelorus Capital Group Enter into Strategic Arrangement to Operate Humboldt County Cultivation Facility
StateHouse to Provide Project Management, Operational Oversight and Strategic Direction at Humboldt County Cultivation FacilitySAN DIEGO and TORONTO, Aug. 22,...
European Commission Approves TALVEY®▼ (talquetamab), Janssen’s Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses,...
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’...
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across PolandBERKELEY,...
SAB Biotherapeutics Provides Company Update for Q2 2023 Financial Results
SIOUX FALLS, S.D., Aug. 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a...
Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio
ALACHUA, Fla. and TAMPA, Fla., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing...
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox
Phase 1/2 Clinical Trial of TNX-801 for the Prevention of Mpox and Smallpox to Commence Following Submission of an IND...
HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent...
EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA...
Pacific Health Care Organization, Inc. Reports its Results for the Period ended June 30, 2023
Irvine, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Results The Company reported net income of $176,427 or $0.01 per basic and...
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...
Moderna Clinical Trial Data Confirm Its Updated COVID-19 Vaccine Generates Robust Immune Response in Humans Against Widely Circulating Variants
Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variantUpdated...
72-Provider FQHC Implements eClinicalWorks Population Health Solutions for Improved Screening and Compliance
eClinicalWorks population health solutions streamline patient data for Connecticut Institute for Communities, Inc.WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud EHR,...
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
Initiated Phase 2 study in COVID-19 with monovalent and bivalent, modified mRNA vaccine candidates; continued execution on infectious disease development...
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency...
Nanox Announces Second Quarter of 2023 Financial Results and Provides Business Update
Reports progress towards global supply chain development Ended the second quarter of 2023 with cash, cash equivalents, restricted cash and...
Tonix Pharmaceuticals to Present at the August Virtual Investor Summit
CHATHAM, N.J., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products...
Eagle Pharmaceuticals Reiterates 2023 Adjusted non-GAAP EBITDA and Adjusted non-GAAP E¹ Guidance
-- FY 2023 Adjusted non-GAAP EBITDA expected to be $78.0 - $84.0 million1 ---- FY 2023 Adjusted non-GAAP earnings per...
Advanced Health Intelligence Obtains Overseas R&D Reimbursement Under Australia’s Research and Development Tax Incentive Scheme (R&DTI)
South Perth, Australia--(Newsfile Corp. - August 17, 2023) - Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ("AHI" or the...